CSSP.F Stock Overview
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
NIOX Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.75 |
| 52 Week High | UK£0.77 |
| 52 Week Low | UK£0.65 |
| Beta | 0.92 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 63.04% |
| 5 Year Change | 89.87% |
| Change since IPO | -84.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| CSSP.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how CSSP.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CSSP.F performed against the US Market.
Price Volatility
| CSSP.F volatility | |
|---|---|
| CSSP.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CSSP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CSSP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 92 | n/a | investors.niox.com |
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022.
NIOX Group Plc Fundamentals Summary
| CSSP.F fundamental statistics | |
|---|---|
| Market cap | US$354.20m |
| Earnings (TTM) | US$11.81m |
| Revenue (TTM) | US$45.75m |
29.8x
P/E Ratio7.7x
P/S RatioIs CSSP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSSP.F income statement (TTM) | |
|---|---|
| Revenue | UK£36.80m |
| Cost of Revenue | UK£10.30m |
| Gross Profit | UK£26.50m |
| Other Expenses | UK£17.00m |
| Earnings | UK£9.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.022 |
| Gross Margin | 72.01% |
| Net Profit Margin | 25.82% |
| Debt/Equity Ratio | 0% |
How did CSSP.F perform over the long term?
See historical performance and comparison